Empagliflozin shows efficacy in curbing A1C rates in diabetes

05/8/2013 | Medscape (free registration)

Empagliflozin monotherapy showed A1C benefits comparable with metformin treatment in type 2 diabetes patients, a study presented at the American Association of Clinical Endocrinologists annual meeting indicated. Researchers also found patients who used empagliflozin as an add-on to metformin therapy attained better fasting plasma glucose levels and greater reductions in body weight at 90 weeks than those who took sitagliptin as an add-on.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC